1 week Ago By Defense World Staff
Norges Bank purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 34,044 shares of the company’s stock, valued at approximately $507,000.
Other institutional investors also recently made changes to their positions in the company. R Squared Ltd bought a new stake in Arcus Biosciences during the fourth quarter worth approximately $26,000. US Bancorp DE increased its position in shares of Arcus Biosciences by 2,432.
0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after purchasing an additional 6,615 shares during the period. AXQ Capital LP bought a new stake in shares of Arcus Biosciences in the 4th quarter worth $160,000.
KLP Kapitalforvaltning AS acquired a new stake in shares of Arcus Biosciences in the fourth quarter valued at $207,000. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Arcus Biosciences by 19.2% in the fourth quarter.
Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock valued at $223,000 after buying an additional 2,410 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Arcus BiosciencesIn related news, CEO Terry J. Rosen acquired 19,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average cost of $10.
18 per share, with a total value of $201,564.00. Following the completion of the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at approximately $26,001,348.
80. This trade represents a 0.78 % increase in their position.
The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Yasunori Kaneko bought 20,000 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was bought at an average price of $10.
06 per share, with a total value of $201,200.00. Following the transaction, the director now owns 28,400 shares in the company, valued at approximately $285,704.
This represents a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here.
12.30% of the stock is currently owned by insiders. Arcus Biosciences Stock PerformanceShares of RCUS opened at $8.
09 on Friday. Arcus Biosciences, Inc. has a one year low of $6.
50 and a one year high of $18.98. The company has a 50-day moving average of $9.
70 and a two-hundred day moving average of $13.60. The company has a debt-to-equity ratio of 0.
08, a current ratio of 5.24 and a quick ratio of 5.24.
The stock has a market cap of $850.04 million, a price-to-earnings ratio of -2.57 and a beta of 1.
54. Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.
03) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14.
Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.
The firm had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million.
On average, equities research analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.
Wall Street Analysts Forecast GrowthRCUS has been the topic of a number of research analyst reports. Bank of America lowered their target price on Arcus Biosciences from $22.00 to $17.
00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $24.
00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley cut their target price on shares of Arcus Biosciences from $36.00 to $25.
00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, Arcus Biosciences presently has an average rating of “Buy” and an average target price of $30.25.Get Our Latest Research Report on RCUSArcus Biosciences Company Profile (Free Report)Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.Further ReadingFive stocks we like better than Arcus BiosciencesOptions Trading – Understanding Strike PriceRobinhood Strategies Could Be a Game-Changer for Young InvestorsUpcoming IPO Stock Lockup Period, ExplainedAre These 3 Retail Stocks Oversold or Really in Trouble?Should You Add These Warren Buffett Stocks to Your Portfolio?IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadWant to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc.
(NYSE:RCUS – Free Report)..
